Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CCND1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CCND1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CCND1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CCND1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CCND1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CCND1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CCND1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CCND1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CCND1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CCND1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CCND1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:004593119 | Thyroid | PTC | positive regulation of mitotic cell cycle | 65/5968 | 121/18723 | 5.08e-07 | 8.26e-06 | 65 |
GO:0009314111 | Thyroid | PTC | response to radiation | 195/5968 | 456/18723 | 5.10e-07 | 8.27e-06 | 195 |
GO:0031667113 | Thyroid | PTC | response to nutrient levels | 201/5968 | 474/18723 | 7.00e-07 | 1.10e-05 | 201 |
GO:00094117 | Thyroid | PTC | response to UV | 76/5968 | 149/18723 | 8.97e-07 | 1.36e-05 | 76 |
GO:00000829 | Thyroid | PTC | G1/S transition of mitotic cell cycle | 102/5968 | 214/18723 | 9.48e-07 | 1.43e-05 | 102 |
GO:00448439 | Thyroid | PTC | cell cycle G1/S phase transition | 112/5968 | 241/18723 | 1.37e-06 | 1.96e-05 | 112 |
GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
GO:19019878 | Thyroid | PTC | regulation of cell cycle phase transition | 167/5968 | 390/18723 | 2.97e-06 | 3.87e-05 | 167 |
GO:007190210 | Thyroid | PTC | positive regulation of protein serine/threonine kinase activity | 93/5968 | 200/18723 | 1.01e-05 | 1.12e-04 | 93 |
GO:1901654113 | Thyroid | PTC | response to ketone | 90/5968 | 194/18723 | 1.56e-05 | 1.65e-04 | 90 |
GO:0010038112 | Thyroid | PTC | response to metal ion | 157/5968 | 373/18723 | 1.80e-05 | 1.86e-04 | 157 |
GO:004277010 | Thyroid | PTC | signal transduction in response to DNA damage | 81/5968 | 172/18723 | 2.07e-05 | 2.08e-04 | 81 |
GO:00459307 | Thyroid | PTC | negative regulation of mitotic cell cycle | 105/5968 | 235/18723 | 2.41e-05 | 2.39e-04 | 105 |
GO:19019917 | Thyroid | PTC | negative regulation of mitotic cell cycle phase transition | 83/5968 | 179/18723 | 3.34e-05 | 3.17e-04 | 83 |
GO:004544418 | Thyroid | PTC | fat cell differentiation | 102/5968 | 229/18723 | 3.66e-05 | 3.40e-04 | 102 |
GO:0061458112 | Thyroid | PTC | reproductive system development | 173/5968 | 427/18723 | 8.70e-05 | 7.23e-04 | 173 |
GO:009006816 | Thyroid | PTC | positive regulation of cell cycle process | 103/5968 | 236/18723 | 9.03e-05 | 7.50e-04 | 103 |
GO:190402912 | Thyroid | PTC | regulation of cyclin-dependent protein kinase activity | 49/5968 | 98/18723 | 1.40e-04 | 1.09e-03 | 49 |
GO:200004515 | Thyroid | PTC | regulation of G1/S transition of mitotic cell cycle | 66/5968 | 142/18723 | 1.86e-04 | 1.41e-03 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCND1 | SNV | Missense_Mutation | rs755986542 | c.778N>T | p.Arg260Cys | p.R260C | P24385 | protein_coding | deleterious(0.03) | benign(0.218) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.859N>A | p.Pro287Thr | p.P287T | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
CCND1 | SNV | Missense_Mutation | | c.859N>A | p.Pro287Thr | p.P287T | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CCND1 | SNV | Missense_Mutation | novel | c.701C>T | p.Ser234Phe | p.S234F | P24385 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD |
CCND1 | SNV | Missense_Mutation | | c.859C>A | p.Pro287Thr | p.P287T | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.405G>T | p.Glu135Asp | p.E135D | P24385 | protein_coding | tolerated(0.69) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CCND1 | SNV | Missense_Mutation | | c.860N>A | p.Pro287His | p.P287H | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.694N>C | p.Phe232Leu | p.F232L | P24385 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
CCND1 | SNV | Missense_Mutation | | c.718G>A | p.Asp240Asn | p.D240N | P24385 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.512C>T | p.Ala171Val | p.A171V | P24385 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | NIFEDIPINE | NIFEDIPINE | 10051745 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | fluorouracil | FLUOROURACIL | 23567490 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | methotrexate | METHOTREXATE | 12972956,16870553 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | lapatinib | LAPATINIB | |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | ACETAMINOPHEN | ACETAMINOPHEN | 11896290 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | ABT-263 | NAVITOCLAX | |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | PALBOCICLIB | PALBOCICLIB | 24417566 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | TROGLITAZONE | TROGLITAZONE | 14764597 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | MTX | METHOTREXATE | 12972956 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | MPA | PROGESTERONE | 16123159 |